BACKGROUND: Among patients on osteoporosis therapy, including oral bisphosphonates (BIS), upper gastrointestinal (GI) conditions have been linked with lower adherence to treatment and increased treatment discontinuation in clinical practice. Patients who are nonadherent to treatment have a higher risk of osteoporotic fractures and, consequently, have greater use of health care services. The burden of upper gastrointestinal events on health care resource utilization (HCRU) among women initiating oral BIS has not been well investigated.
O ral bisphosphonates (BIS) are the most commonly prescribed first-line treatment for osteoporosis (OP) in postmenopausal women in the United States and have proven to be effective in reducing the risk of fracture in clinical trials. [1] [2] [3] [4] [5] [6] [7] However, gastrointestinal (GI) events are a common complaint of patients taking BIS, often manifesting as dyspepsia, nausea, abdominal pain, and, less frequently, esophagitis and esophageal/duodenal ulcers. [8] [9] [10] [11] In clinical practice, approximately 25% of women with OP experience GI events before OP treatment initiation. 8 Previous studies have shown that the proportion of women experiencing GI events prior to initiating oral BIS therapy is similar to the proportion of women experiencing new GI events after initiating oral BIS therapy. 8 However, occurrence of GI events may pose an incremental health care resource burden.
The consequences of GI events can be poor adherence to therapy and, ultimately, negative clinical and economic outcomes. Patients taking oral BIS who are most symptomatic for
• Previous observational studies have linked upper gastrointestinal conditions among patients taking osteoporosis therapies, including oral bisphosphonates, to poor adherence to treatment and therapy discontinuation.
What is already known about this subject
• Patients who are nonadherent or nonpersistent to osteoporosis therapy are at higher risk of fracture and consequently have greater use of health care services.
• The association between gastrointestinal events and health care resource utilization has not been well investigated.
• This study evaluated the association between upper gastrointestinal events and health care resource utilization among women who had initiated oral bisphosphonate treatment and had no recent history of gastrointestinal diagnoses.
• Following initiation of oral bisphosphonate treatment, women who experienced upper gastrointestinal events incurred significantly greater all-cause and osteoporosis-related medical resource utilization than their counterparts who did not experience upper gastrointestinal events.
• Upper gastrointestinal events were associated with 1.5 to 3. 5 greater odds of utilizing osteoporosis-related inpatient, outpatient, and emergency room services.
Data Source
We used the i3 Invision Datamart database for analysis. This large national claims database was designed primarily to support health care outcomes research and other research initiatives. The database contained health care claims for more than 80 million managed care enrollees in more than 45 health plans throughout the United States during 2001-2011. Data elements used in the current analysis included health plan enrollment records, patient demographics, type of insurance, medical claims (from inpatient and outpatient facilities), and prescription pharmacy claims. The database included data on approximately 3 million subjects with a diagnosis of OP, OP-related fracture, and/or a prescription for a medication used to treat or prevent OP (e.g., BIS and estrogens). Primary and secondary diagnoses from the medical records were identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes; procedures codes were identified by Current Procedural Terminology (CPT) codes and prescription pharmacy records were identified by National Drug Code numbers.
Patient Identification
We first identified women who initiated oral BIS therapy during January 1, 2001, to June 30, 2011. Oral BIS therapy was defined as the presence of a prescription claim for alendronate, ibandronate, or risedronate. The first pharmacy claim for BIS side effects have higher odds of nonadherence to therapy, 12 and in clinical practice, 26% to 76% of patients who discontinued oral BIS therapy did so primarily because of GI intolerance. [13] [14] [15] Patients who are nonadherent to OP therapies, including BIS, are at higher risk of vertebral and nonvertebral fractures, incur higher medical costs, and are more likely to be hospitalized. [16] [17] [18] [19] [20] [21] GI events in women initiating primarily oral BIS medications have also been linked to diminished health-related quality of life and lower treatment satisfaction, which may lead to treatment discontinuation, worse clinical outcomes, and, ultimately, greater use of health care services. 8 However, the burden of GI events to health care resource utilization in women taking oral BIS has not been well investigated. The objective of this study was to examine the association of upper GI events with all-cause and OP-related health care resource utilization among women who were initiating BIS.
■■ Methods
A retrospective matched cohort study design was used to examine the association between upper GI events after initiation of treatment and all-cause and OP-related health care resource utilization among osteoporotic patients who were prescribed oral BIS therapy. All data were de-identified and accessed in compliance with the Health Insurance Portability and Accountability Act privacy guidelines. Because patients with a history of GI events are at increased risk of subsequent GI events, the occurrence of some GI events after treatment initiation may be associated with GI events prior to treatment initiation. 23 To eliminate potential bias associated with GI events prior to treatment initiation on health care utilization after treatment initiation, patients experiencing any (upper or lower) GI events during the 1-year period before treatment initiation were also excluded. GI events (upper or lower) were defined by the presence of a medical claim (inpatient or outpatient) with a GI-related ICD-9-CM diagnostic code or CPT procedural code. The relevant codes are shown in the Appendix (available in online article).
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FIGURE 1
Study Design
Definition of Cases and Controls
Patients who met inclusion criteria were grouped into 2 cohorts: case and control ( Figure 1 ). The case cohort included patients who experienced ≥ 1 upper GI event within the first 4 months following the date of treatment initiation. The date of the first upper GI event after treatment initiation was defined as the index date for cases. The control cohort included patients who did not experience any upper GI event within the first 4 months following treatment initiation. A randomly assigned date within the first 4 months following treatment initiation was set as the index date for controls. The random assignment of the index date for controls was based on the empirical distribution of time to the index date for the case group. For both groups, the follow-up period extended from the index date to 6 months after the index date. Upper GI events were defined as the presence of a medical claim (inpatient or outpatient) with an upper GI-related ICD-9-CM diagnostic code (ICD-9-CM codes included 530.81, 530.82, 531.xx, 532.xx, 533.xx, 578.xx, 530.1x, 530.2x, 530.3x, 530.4x, 530.5x, 530.6x, 530.7x, 535.0x, 535.4x, 535.5x, 535.6x, 536.2x, 536.8x, 787.0x, 787.1x, 787.2x, and 789.0x). For example, upper GI events included esophagitis, ulcer of esophagus, stricture of esophagus, perforation of esophagus, dyskinesia of esophagus, diverticulum of esophagus, gastroesophageal laceration-hemorrhage syndrome, esophageal reflux, esophageal hemorrhage, gastric ulcer, duodenal ulcer, peptic ulcer, gastritis, duodenitis, persistent vomiting, dyspepsia, GI hemorrhage, nausea and vomiting, heartburn, dysphagia, and abdominal pain (see Appendix).
Matching of Cases and Controls
Cases were matched to controls using propensity score matching to ensure balanced pre-index date patient characteristics between both cohorts. Patient characteristics assessed during the 12-month pre-index period were used in the propensity score matching. First, the cohorts were stratified by age group (< 65 years and ≥ 65 years as of the index date) and the index year. Second, within each stratum, a logistic regression model was fitted to estimate the propensity of experiencing an upper GI event based on the pre-index patient characteristics. The pre-index patient characteristics that were included in the model were age group; type of insurance (health maintenance organization [ 24 total number of pre-index hospitalizations; and total pre-index health care costs. Concomitant use of the following medications was ascertained: gastro-protective agents, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAID), and estrogen. Finally, using the 1-to-1 nearest-neighbor matching, cases were then matched to controls based on the propensity scores estimated by the logistic regression model. Cases were not matched if there were no controls with an estimated propensity score within the allowable range (caliper: 0.2 standard deviations of the propensity score) of the cases. Cases that were not matched to controls were excluded from the analysis.
Baseline Characteristics of Patients
The following demographic and clinical characteristics of patients were captured during the baseline period (1 year preindex date): (a) age on the index date categorized into 4 groups (55-64, 65-74, 75-84, and ≥ 85 years); (b) type of insurance (HMO, PPO, POS, or other); (c) CCI score (0, 1, 2, ≥ 3); (d) baseline fracture (any, vertebral, hip, or other); (e) baseline use of gastroprotective agents (proton pump inhibitor, H2-antagonist, or cytoprotectant), NSAIDs, glucocorticoids, and estrogen; and (f) baseline comorbid conditions.
Outcomes
Health Care Resource Utilization. Total health care resource utilization was categorized as medical or pharmacy utilization. Medical utilization included all services conducted in the inpatient and outpatient settings and was categorized into inpatient, outpatient, emergency room (ER), and other, based on the place at which the service was performed. For instance, services performed in inpatient hospital, inpatient psychiatric facilities, and comprehensive inpatient rehabilitation facilities were classified as inpatient claims. All visits in the same category in a single day were considered as a single service use. For inpatient and ER episodes, services performed on consecutive days were combined into 1 episode to ensure that 2 distinct episodes were at least 1 day apart. We also examined Medical Utilization. Medical utilization was analyzed in 2 domains in this study: (1) all-cause medical utilization, which included medical services related to any medical cause, and (2) OP-related medical utilization, which included only services with a primary or secondary diagnosis of osteoporosis (ICD-9-CM 733.0x code). We calculated the health care resource utilization rates as the percentage of patients utilizing each type of service. The total number of hospitalizations, outpatient visits, ER visits, and other medical resource utilization were also determined for each patient.
Statistical Analyses
Descriptive statistics were examined by cohort. Categorical variables were described by their frequency and continuous variables by their mean and standard deviation. Pre-index baseline characteristics were compared between cases and controls using the Wilcoxon rank sum test for continuous variables and chi-square test for categorical variables. Matchadjusted analysis was used to examine the association between upper-GI events and all-cause health care resource utilization and OP-related health care resource utilization during the 6-month post-index period. Differences in all-cause and OP-related health care resource utilization rates between the 2 cohorts (cases and controls) were assessed using McNemar's tests, whereas differences in average number of health care resource utilization were assessed by Wilcoxon signed rank tests. All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).
■■ Results Study Population and Patient Baseline Characteristics
Of the 680,069 women who initiated oral OP therapy, 62,863 patients met the study inclusion criteria (Figure 2 ). The majority of patients (n = 340,855) were excluded for lack of continuous enrollment 1 year before and 10 months after initiation of OP treatment. The rate of upper GI events was 7.6% within 4 months among patients initiating BIS in the studied population. A total of 4,751 patients matched the case definition, and 4,739 of these patients were successfully matched 1:1 with control patients; 12 cases could not be matched within the allowable range and were excluded. Among the matched case patients, the mean (median) time to the first upper GI event was 54.7 (52) days. The baseline characteristics of the patients are presented in Table 1 . For both cases and controls, mean age was 65 years, and 63.3% of patients were aged 55-64 years. Mean CCI score was similar for cases (0.7) and controls (0.7), and 59.6% of patients had a CCI score of 0. A total of 228 cases and 227 controls (4.8%) experienced 1 or more fractures during the baseline period. The most common concomitant medications were NSAIDs prescribed for 31.9% of patients, followed by estrogen (22.6%) and gastroprotective agents (21.3%). The most frequently diagnosed comorbid conditions were hypertension (45.8%), OP (45.3%), osteopenia (38.5%), musculoskeletal pain (34.0%), and menopause/menopausal symptoms (29.7%). No differences in distribution of patient baseline characteristics were observed between matched cases and controls.
Health Care Resource Utilization
Six-month resource utilization rates by cohort are presented in Table 2 . Patients with a posttreatment upper GI event (cases) had a significantly higher rate of all-cause resource utilization for all service types (i.e., outpatient, inpatient, ER, and other medical services) compared with patients without posttreatment upper GI events (controls). Table 3 displays the average number of health care resource use within 6 months after index date for both cohorts. Cases had a higher number of episodes of all-cause health care service utilization compared with the controls (outpatient: 8.77 vs. 5.80; inpatient: 0.32 vs. 0.09; ER: 0.30 vs. 0.22; all P < 0.001). The same pattern of significantly higher service utilization was evident for OP-related health care resource use.
Average Number of Health Care Resource Use
■■ Discussion
This study assessed the association between upper GI events and all-cause and OP-related health care resource utilization among osteoporotic patients initiating oral BIS in a large U.S. managed care population. We excluded patients with a prior history of GI events to avoid the potential bias of preexisting GI events and employed propensity score matching for a more robust evaluation of the contribution of upper GI events to health care utilization. Our results suggest that patients with an upper GI event have a significantly higher rate of all-cause and OP-related resource utilization for all service categories, including inpatient and ER services, compared with patients without GI events after treatment.
Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population
In our sample, 7.6% of patients initiating oral BIS therapy experienced an upper GI event after treatment. This rate is lower than results reported in previous, smaller scale observational studies showing that 10%-33% of patients experienced an upper GI or any GI event during oral BIS therapy. [13] [14] [15] In our study, only upper GI events that resulted in medical health care utilization were considered, whereas the previous studies were based on self-reported GI symptoms that may or may not have resulted in medical resource utilization. Further, we excluded patients with prior GI events to minimize the potential impact of preexisting conditions on the GI event rate, while the earlier studies did not. Nevertheless, 21% of patients overall were using prescription gastroprotective agents during the baseline period, suggesting that GI symptoms are relatively common in this population.
In this study, the occurrence of upper GI events after initiation of BIS treatment may be associated with use of BIS or background conditions, which commonly exist in elderly osteoporotic women. 
a similar pattern of significantly higher use for all service categories among patients with upper GI events. At baseline, concurrent use of gastroprotective agents was similar between cases and controls, 21.7% and 21.0%, respectively. After initiating oral BIS therapy, the percentage of case patients taking gastroprotective agents increased considerably from baseline (34.2%), while usage in the control group declined from baseline (16.6%). The most common gastroprotective agents used were proton pump inhibitors and H2 receptor antagonists; these agents are indicated for prevention and treatment of gastric and duodenal ulcers and gastroesophageal reflux disease.
The occurrence of upper GI events was a risk factor for all-cause and OP-related health care utilization among women initiating BIS, regardless of whether the upper GI events were caused by use of BIS, use of other medications, or concomitant medical conditions. Although upper GI events with relatively less severity, such as abdominal pains, may not lead to hospitalization or other health care resource utilization, patients who experienced any upper GI events after BIS treatment initiation had significantly greater odds of all-cause health care utilization, with the most pronounced differences evident for outpatient services (18.3 higher odds) and inpatient stays (3.7 higher odds), compared with control patients. OP-related service utilization followed 
and missing codes. Claims data do not provide insight into the possible cause of upper GI events, such as oral BIS dosing schedule, compliance with dosing instructions and medication adherence, or something unrelated to osteoporosis medications. We cannot infer that oral BIS initiation causes upper GI events. However, significant comorbid GI disease prior to initiating oral BIS therapy is unlikely to be a confounding factor because patients with any GI events in the year prior to initiating oral BIS therapy were excluded. Nevertheless, the upper GI events that distinguished cases from controls are based only on those events that resulted in medical service utilization and were coded as such. Thus, less severe GI events that did not result in a medical encounter may have been present in both cohorts prior to and during the study, and these events would not have been captured. Although we employed propensity scores to match case and control patients for clinical and demographic characteristics, there may have been other, unmeasured factors that potentially influenced results. For example, bone mineral density tests results (e.g., T-scores) were not available in the claims database. Finally, our results are based on patients with commercial insurance in a stable, managed care setting and may not be generalizable to patients with other forms of insurance or the uninsured.
The findings from our study aid in understanding the health care resource utilization burden associated with upper GI events among patients newly initiating oral BIS therapy. Although this study cannot imply a causal relationship between upper GI events and BIS use as per study design, health care practitioners must remain cognizant of upper GI events among patients on OP medications, should routinely ask about preexisting upper GI disorders and concurrent medication history, and should consider alternate treatments for patients with upper GI events. Furthermore, the burden associated with upper GI events can have implications for managed care health plans from a medical resource use and pharmacy perspective. A recent study reported an association between GI events following oral BIS initiation and greater risk of discontinuation or switching to alternate therapy. 25 Patients discontinuing therapy due to GI intolerance will require prompt approval of alternative OP treatment to reduce fracture risk and the consequential medical resource burden.
Limitations
There are several limitations to our study, and the results should be interpreted in this context. Our results are based on administrative claims data, which are subject to coding errors Study concept and design were created by Modi, with assistance from the other authors. Sajjan, Gold, and Fan collected the data, and data interpretation was performed by Modi and Sajjan, with assistance from the other authors. The manuscript was written by Sajjan, Yang, Modi, and Gold, with assistance from Fan, and revised by Modi, Yang, and Fan, with assistance from Gold and Sajjan.
